Dynavax Technologies (NASDAQ:DVAX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAXFree Report) from a hold rating to a buy rating in a research note released on Tuesday.

Separately, HC Wainwright upped their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday.

Get Our Latest Stock Report on Dynavax Technologies

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $12.48 on Tuesday. The firm has a market capitalization of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The business has a fifty day simple moving average of $12.76 and a 200 day simple moving average of $11.65. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.41. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE grew its stake in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies during the 3rd quarter worth $45,000. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies during the 3rd quarter worth $89,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Articles

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.